Merck, Eisai discontinue late-stage study for combo cancer therapy
Send a link to a friend
[August 26, 2023]
(Reuters) -Merck & Co and partner Eisai said on Friday they will
shut down a late-stage study testing an experimental combination therapy
for a type of head and neck cancer after an interim analysis showed it
failed to prolong lives of patients.
The therapy, Merck's blockbuster drug Keytruda in combination with
Eisai's Lenvima, failed to show statistical significance in extending
overall survival, one of the three main goals of the study, the
companies said.
The companies were testing the combination for head and neck squamous
cell carcinoma — a cancer that develops in the mucous membranes of the
mouth, nose and throat — in patients with recurrent or metastatic form
of the disease and whose tumors contain a protein called PD-L1.
![](http://archives.lincolndailynews.com/2023/Aug/26/images/ads/current/sunag_sda_FAIR_2023.png)
This type of cancer is especially common in parts of Southeast Asia, and
the companies estimate it to lead to more than 66,000 new diagnoses in
the United States this year.
"Our clinical program is designed to help accelerate our efforts to
tackle difficult-to-treat, advanced cancers, and while the outcome may
not always be what we anticipate, we know that this is part of clinical
development," said Eisai executive Corina Dutcus.
[to top of second column]
|
![](../images/082623PIX/health43.jpg)
Signage is seen at the Merck & Co.
headquarters in Kenilworth, New Jersey, U.S., November 13, 2021.
REUTERS/Andrew Kelly/File Photo
![](http://archives.lincolndailynews.com/2023/Aug/26/images/ads/current/debbiesflora_lda_081123.png) The therapy met other main goals of
reducing tumor size and improving the time to death or disease
worsening after treatment compared to placebo.
The companies are testing the combination to treat a range of
cancers, including those affecting the lungs and stomach.
The Keytruda-Lenvima combination therapy is approved in the United
States for the treatment of a type of kidney cancer and certain
types of cancers in the lining of the uterus.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shinjini Ganguli
and Shilpi Majumdar)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
![](http://archives.lincolndailynews.com/2023/Aug/26/images/ads/current/charrons_bch_2022.png) |